SEC Filing Summary: AspenBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by AspenBio, Inc. on October 4, 2004, covering events occurring on October 1, 2004. The registrant is incorporated in Colorado with principal executive offices in Castle Rock, CO. Note: The request metadata referenced "Riot Platforms, Inc." and the date "2004 Oct 01," but the source text explicitly identifies the registrant as AspenBio, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors expanded the number of members to five.
- Director Appointment: David Welch was appointed to fill the vacancy created by the expansion.
- Committee Assignments: Mr. Welch was appointed Chair of the Audit Committee and a member of the Compensation, Nominating, and Corporate Governance Committees.
- Equity Grant: Mr. Welch received options to purchase 100,000 shares of common stock at an exercise price of $0.76 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document strictly reports the appointment of a director and associated equity compensation.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors and the specific roles assigned to David Welch.
- Confirm the terms of the stock option grant (100,000 shares at $0.76) and its alignment with existing director compensation policies.
- Review the attached Press Release (Exhibit 99.1) for additional context on the strategic rationale for the board expansion.